Past the Bottleneck: Engineering Delicate Bespoke MRD Assays

This webinar, brought to you by Twist Bioscience, will be hosted live and available on-demand.

Monday, April 13th, 2026
11:00 AM – 12:00 PM ET

Tumor-informed liquid biopsy stands as the gold standard for monitoring minimal residual disease (MRD), but scientists face significant hurdles in assay development and adoption. Operational complexity, workflow bottlenecks, and the need to deliver highly personalized, rapid, and sensitive testing at scale continue to impede progress.

In this live roundtable webinar, brought to you by Twist Bioscience, leading experts will discuss the technical and operational challenges that limit MRD testing and assay development, while highlighting emerging approaches to address them.

Shawn Gorda  Director, NGS Product Management Twist Bioscience